Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Gastroenterology · Esophageal and Esophagogastric Junction Adenocarcinoma

Validation & Orientation: Understanding Your Diagnosis

At a Glance

Esophageal adenocarcinoma (EAC) and esophagogastric junction (EGJ) cancers often develop from chronic acid reflux and Barrett's esophagus. Today, these conditions are highly treatable using a team-based approach and multimodal therapies that combine surgery, radiation, chemotherapy, and immunotherapy.

Receiving a diagnosis of esophageal adenocarcinoma (EAC) or esophagogastric junction (EGJ) adenocarcinoma can be overwhelming. However, it is important to know that you are not alone, and the landscape of care for these conditions is changing rapidly. While these were once considered difficult-to-treat diseases, modern multimodal therapy—which combines different types of treatment—has significantly improved the outlook for many patients [1][2].

Understanding Your Diagnosis

To understand these cancers, it helps to know where they start. The esophagus is the muscular tube that carries food from your throat to your stomach. The esophagogastric junction (EGJ) is the specific area where the esophagus meets the stomach.

Adenocarcinoma is a type of cancer that begins in glandular cells [3]. In the esophagus, these cells usually develop through a process called metaplasia. This often happens because of chronic gastroesophageal reflux disease (GERD), where stomach acid splashes back into the esophagus [4]. Over time, the body tries to protect the esophageal lining by changing its cells into a tougher, more stomach-like type known as Barrett’s esophagus [3][5]. While most people with Barrett’s esophagus never develop cancer, it is considered the primary “precursor” or starting point for EAC [4][6].

A Rising Trend in the West

You may wonder why this is happening now. The incidence of EAC and EGJ adenocarcinoma has been steadily increasing, particularly in high-income Western countries [7][8]. In fact, in many of these regions, adenocarcinoma has surpassed other types of esophageal cancer to become the most common form [8]. Because of this trend, there has been a massive increase in research, leading to the sophisticated treatments available today [9].

The Power of the Team: Why the MDT Matters

Current medical guidelines emphasize that these cancers should not be managed by a single doctor. Instead, you should be cared for by a Multidisciplinary Team (MDT) [10][11]. This team typically includes:

  • Gastroenterologists: Doctors who specialize in the digestive system and perform endoscopies.
  • Surgical Oncologists: Surgeons who specialize in removing tumors.
  • Medical Oncologists: Doctors who treat cancer with medicine, like chemotherapy or immunotherapy.
  • Radiation Oncologists: Doctors who use high-energy beams to shrink tumors.
  • Pathologists and Radiologists: Specialists who analyze your tissue samples and scans to ensure the most accurate diagnosis [10][12].

Research shows that when an MDT reviews a patient’s case, it leads to more accurate staging and a more individualized treatment plan, which is associated with better results for patients [10][13].

A New Era of Treatment

The “gold standard” for treating localized EAC and EGJ cancer has shifted from surgery alone to multimodal therapy [14]. This often involves:

  1. Neoadjuvant Therapy: Treatment given before surgery (such as chemotherapy or a combination of chemotherapy and radiation) to shrink the tumor and kill microscopic cancer cells [1][15].
  2. Immunotherapy: A newer type of treatment that helps your own immune system find and attack cancer cells. Immunotherapy is now a standard part of care for many patients, both in the advanced setting and as a follow-up after surgery if any cancer cells remain [16][17].

These advancements mean that your care team has more “tools in the toolbox” than ever before, allowing them to tailor a plan specifically to the biology of your tumor [10][18].

Common questions in this guide

What is esophageal adenocarcinoma (EAC)?
Esophageal adenocarcinoma is a type of cancer that starts in the glandular cells of the esophagus, often at the junction where it meets the stomach. It frequently develops from a condition called Barrett's esophagus, which is caused by long-term chronic acid reflux.
What is the esophagogastric junction (EGJ)?
The esophagogastric junction is the specific area in your digestive tract where the esophagus connects to your stomach. Cancers that form in this transition zone are called EGJ adenocarcinomas and require specialized, highly coordinated treatment strategies.
Why is my cancer care managed by a Multidisciplinary Team (MDT)?
An MDT includes various specialists like surgeons, medical oncologists, and gastroenterologists who work together to review your case. This team approach leads to more accurate staging and a personalized treatment plan, which is proven to improve patient outcomes.
What is multimodal therapy for esophageal cancer?
Multimodal therapy combines different types of treatment, such as chemotherapy, radiation, and surgery, to fight the cancer. This approach often involves giving neoadjuvant treatments before surgery to shrink tumors, which is now the standard of care for localized tumors.
How does immunotherapy help treat EAC and EGJ cancers?
Immunotherapy helps your body's own immune system recognize and attack cancer cells. It has become a standard part of care for many patients, and it can be used either for advanced stages of disease or after surgery to target any remaining microscopic cancer cells.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my case been reviewed by a formal Multidisciplinary Tumor Board (MDT), and which specialists were involved?
  2. 2.What is the specific location of my tumor according to the 'Siewert classification,' and how does that affect my treatment plan?
  3. 3.Am I a candidate for 'perioperative' chemotherapy (like the FLOT regimen) or 'neoadjuvant' chemoradiation (like the CROSS regimen)?
  4. 4.Have my biomarkers (like HER2, PD-L1, and MSI status) been tested yet, and how will those results guide my care?
  5. 5.If I have residual disease after surgery, will I be a candidate for adjuvant immunotherapy like nivolumab?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Increasing Use of PET-CT, Neoadjuvant Treatment, Minimally Invasive Approach and Surgical Radicality in Esophageal Cancer Surgery are Associated with Improved Short- and Long-term Outcomes in Real-World Setting.

    Junttila A, Saviaro H, Huhta H, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2022; (26(4)):742-749 doi:10.1007/s11605-022-05279-z.

    PMID: 35217930
  2. 2

    Racial Disparities in Esophageal Cancer.

    Pickens A

    Thoracic surgery clinics 2022; (32(1)):57-65 doi:10.1016/j.thorsurg.2021.09.004.

    PMID: 34801196
  3. 3

    Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.

    Schlottmann F, Molena D, Patti MG

    Updates in surgery 2018; (70(3)):339-342 doi:10.1007/s13304-018-0564-y.

    PMID: 30039277
  4. 4

    Barretts's carcinogenesis.

    Mukaisho KI, Kanai S, Kushima R, et al.

    Pathology international 2019; (69(6)):319-330 doi:10.1111/pin.12804.

    PMID: 31290583
  5. 5

    The Immune Underpinnings of Barrett's-Associated Adenocarcinogenesis: a Retrial of Nefarious Immunologic Co-Conspirators.

    Tambunting L, Kelleher D, Duggan SP

    Cellular and molecular gastroenterology and hepatology 2022; (13(5)):1297-1315 doi:10.1016/j.jcmgh.2022.01.023.

    PMID: 35123116
  6. 6

    Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition.

    Nowicki-Osuch K, Zhuang L, Jammula S, et al.

    Science (New York, N.Y.) 2021; (373(6556)):760-767 doi:10.1126/science.abd1449.

    PMID: 34385390
  7. 7

    Current and Future Treatment Strategies for Esophageal Adenocarcinoma.

    Quaas A

    Cancers 2020; (12(10)) doi:10.3390/cancers12102930.

    PMID: 33053623
  8. 8

    Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.

    Arnold M, Laversanne M, Brown LM, et al.

    The American journal of gastroenterology 2017; (112(8)):1247-1255 doi:10.1038/ajg.2017.155.

    PMID: 28585555
  9. 9

    Etiologic factors for Barrett's esophagus: toward countermeasures in Asia.

    Iijima K

    Expert review of gastroenterology & hepatology 2024; (18(8)):407-420 doi:10.1080/17474124.2024.2386367.

    PMID: 39072626
  10. 10

    Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

    Zheng YH, Zhao EH

    World journal of gastroenterology 2022; (28(31)):4299-4309 doi:10.3748/wjg.v28.i31.4299.

    PMID: 36159003
  11. 11

    Therapeutic Advances in the Treatment of Gastroesophageal Cancers.

    Li JJ, Rogers JE, Yamashita K, et al.

    Biomolecules 2023; (13(5)) doi:10.3390/biom13050796.

    PMID: 37238666
  12. 12

    Strategies to prevent Barrett's esophagus associated esophageal adenocarcinoma.

    Singh DM, Trindade AJ

    World journal of gastroenterology 2025; (31(39)):108853 doi:10.3748/wjg.v31.i39.108853.

    PMID: 41180794
  13. 13

    Esophageal adenocarcinoma: A dire need for early detection and treatment.

    Joseph A, Raja S, Kamath S, et al.

    Cleveland Clinic journal of medicine 2022; (89(5)):269-279 doi:10.3949/ccjm.89a.21053.

    PMID: 35500930
  14. 14

    Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical.

    Greally M, Ku GY

    Journal of thoracic disease 2019; (11(Suppl 15)):S1855-S1860 doi:10.21037/jtd.2019.08.116.

    PMID: 31632768
  15. 15

    Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines.

    Anker CJ, Dragovic J, Herman JM, et al.

    International journal of radiation oncology, biology, physics 2021; (109(1)):186-200 doi:10.1016/j.ijrobp.2020.08.050.

    PMID: 32858113
  16. 16

    Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.

    Cetin B, Wabl CA, Gumusay O

    Immunotherapy 2023; (15(12)):945-962 doi:10.2217/imt-2022-0287.

    PMID: 37291863
  17. 17

    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

    Kelly RJ, Ajani JA, Kuzdzal J, et al.

    The New England journal of medicine 2021; (384(13)):1191-1203 doi:10.1056/NEJMoa2032125.

    PMID: 33789008
  18. 18

    Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.

    Zhang X, Wang Y, Meng L

    Acta pharmaceutica Sinica. B 2022; (12(3)):1054-1067 doi:10.1016/j.apsb.2021.09.028.

    PMID: 35530133

This page provides general educational information about esophageal and EGJ adenocarcinoma diagnoses. Always consult your multidisciplinary oncology team for specific medical advice and personalized treatment planning.

Get notified when new evidence is published on Adenocarcinoma of the oesophagus and oesophagogastric junction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.